No Changes in T1 Relaxometry After a Mean of 11 Administrations of Gadobutrol.
Journal
Investigative radiology
ISSN: 1536-0210
Titre abrégé: Invest Radiol
Pays: United States
ID NLM: 0045377
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
pubmed:
26
2
2020
medline:
31
3
2021
entrez:
26
2
2020
Statut:
ppublish
Résumé
Quantitative T1 relaxometry is the benchmark in imaging potential gadolinium deposition and known to be superior to semiquantitative signal intensity ratio analyses. However, T1 relaxometry studies are rare, commonly limited to a few target structures, and reported results are inconsistent.We systematically investigated quantitative T1 relaxation times (qT1) of a variety of brain nuclei after serial application of gadobutrol. Retrospectively, qT1 measurements were performed in a patient cohort with a mean number of 11 gadobutrol applications (n = 46) and compared with a control group with no prior gadolinium-based contrast agent administration (n = 48). The following target structures were evaluated: dentate nucleus, globus pallidus, thalamus, hippocampus, putamen, caudate, amygdala, and different white matter areas. Subsequently, multivariate regression analysis with adjustment for age, presence of brain metastases and previous cerebral radiotherapy was performed. No assessed site revealed a significant correlation between qT1 and number of gadobutrol administrations in multivariate regression analysis. However, a significant negative correlation between qT1 and age was found for the globus pallidus as well as anterior and lateral thalamus (P < 0.05 each). No T1 relaxation time shortening due to gadobutrol injection was found in any of the assessed brain structures after serial administration of 11 doses of gadobutrol.
Identifiants
pubmed: 32097141
doi: 10.1097/RLI.0000000000000650
pii: 00004424-202006000-00008
doi:
Substances chimiques
Contrast Media
0
Organometallic Compounds
0
gadobutrol
1BJ477IO2L
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
381-386Références
Radbruch A, Weberling LD, Kieslich PJ, et al. High-signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted images: evaluation of the macrocyclic gadolinium-based contrast agent gadobutrol. Invest Radiol. 2015;50:805–810.
Radbruch A, Haase R, Kieslich P, et al. No signal intensity increase in the dentate nucleus on unenhanced T1-weighted MR images after more than 20 serial injections of macrocyclic gadolinium -based contrast agents. Radiology. 2017;282:699–707.
Weberling LD, Kieslich PJ, Kickingereder P, et al. Increased signal intensity in the dentate nucleus on unenhanced t1-weighted images after gadobenate dimeglumine administration. Invest Radiol. 2015;50:743–748.
Zhang Y, Cao Y, Shih GL, et al. Extent of signal Hyperintensity on unenhanced T1-weighted brain MR images after more than 35 administrations of linear gadolinium-based contrast agents. Radiology. 2017;282:516–525.
Errante Y, Cirimele V, Mallio CA, et al. Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. Invest Radiol. 2014;49:685–690.
Quattrocchi CC, Mallio CA, Errante Y, et al. Gadodiamide and dentate nucleus T1 hyperintensity in patients with meningioma evaluated by multiple follow-up contrast-enhanced magnetic resonance examinations with no systemic interval therapy. Invest Radiol. 2015;50:470–472.
Fretellier N, Granottier A, Rasschaert M, et al. Does age interfere with gadolinium toxicity and presence in brain and bone tissues?: a comparative gadoterate versus gadodiamide study in juvenile and adult rats. Invest Radiol. 2019;54:61–71.
Kanda T, Ishii K, Kawaguchi H, et al. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology. 2013;270:834–841.
Runge VM. Macrocyclic versus linear gadolinium chelates. Invest Radiol. 2015;50:811.
Stojanov DA, Aracki-Trenkic A, Vojinovic S, et al. Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol. Eur Radiol. 2016;26:807–815.
Saake M, Schmidle A, Kopp M, et al. MRI brain signal intensity and relaxation times in individuals with prior exposure to gadobutrol. Radiology. 2019;290:659–668.
Kelemen P, Alaoui J, Sieron D, et al. T1-weighted grey matter signal intensity alterations after multiple administrations of gadobutrol in patients with multiple sclerosis, referenced to white matter. Sci Rep. 2018;8:16844.
Bjørnerud A, Vatnehol SAS, Larsson C, et al. Signal enhancement of the dentate nucleus at unenhanced MR imaging after very high cumulative doses of the macrocyclic gadolinium-based contrast agent gadobutrol: an observational study. Radiology. 2017;285:434–444.
Splendiani A, Corridore A, Torlone S, et al. Visible T1-hyperintensity of the dentate nucleus after multiple administrations of macrocyclic gadolinium-based contrast agents: yes or no? Insights Imaging. 2019;10.
Mallio CA, Lo Vullo G, Messina L, et al. Increased T1 signal intensity of the anterior pituitary gland on unenhanced magnetic resonance images after chronic exposure to gadodiamide. Invest Radiol. 2020;55:25–29.
Young LK, Gandy SJ, Priba L, et al. The impact of different magnetic resonance imaging equipment and scanning parameters on signal intensity ratio measurements in phantoms and healthy volunteers. Invest Radiol. 2018;54:169–176.
Kang KM, Choi SH, Hwang M, et al. T1 shortening in the globus pallidus after multiple administrations of gadobutrol: assessment with a multidynamic multiecho sequence. Radiology. 2018;287:258–266.
Müller A, Jurcoane A, Mädler B, et al. Brain relaxometry after macrocyclic Gd-based contrast agent. Clin Neuroradiol. 2017;27:459–468.
Tedeschi E, Palma G, Canna A, et al. In vivo dentate nucleus MRI relaxometry correlates with previous administration of gadolinium-based contrast agents. Eur Radiol. 2016;26:4577–4584.
Marques JP, Kober T, Krueger G, et al. MP2RAGE, a self bias-field corrected sequence for improved segmentation and T1-mapping at high field. Neuroimage. 2010;49:1271–1281.
Vymazal J, Righini A, Brooks RA, et al. T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content. Radiology. 1999;211:489–495.
Lai PH, Chen C, Liang HL, et al. Hyperintense basal ganglia on T1-weighted MR imaging. Am J Roentgenol. 1999;172:1109–1115.
Oh S-H, Lee K-Y, Im J-H, et al. Chorea associated with non-ketotic hyperglycemia and hyperintensity basal ganglia lesion on T1-weighted brain MRI study. J Neurol Sci. 2002;200:57–62.
Mirowitz SA, Westrich TJ, Hirsch JD. Hyperintense basal ganglia on T1-weighted MR images in patients receiving parenteral nutrition. Radiology. 1991;181:117–120.
Henkelman RM, Watts JF, Kucharczyk W. High signal intensity in MR images of calcified brain tissue. Radiology. 1991;179:199–206.
Brunberg JA, Kanal E, Hirsch W, et al. Chronic acquired hepatic failure: MR imaging of the brain at 1.5 T. Am J Neuroradiol. 1991;12:909–914.
Bradley WG. MR appearance of hemorrhage in the brain. Radiology. 1993;189:15–26.
Mochizuki H, Kamakura K, Masaki T, et al. Atypical MRI features of Wilson's disease: high signal in globus pallidus on T1-weighted images. Neuroradiology. 1997;39:171–174.
Robert P, Violas X, Grand S, et al. Linear gadolinium-based contrast agents are associated with brain gadolinium retention in healthy rats. Invest Radiol. 2016;51:73–82.
Robert P, Fingerhut S, Factor C, et al. One-year retention of gadolinium in the brain: comparison of gadodiamide and gadoterate meglumine in a rodent model. Radiology. 2018;288:424–433.
Jost G, Frenzel T, Boyken J, et al. Gadolinium presence in the brain after administration of the liver-specific gadolinium-based contrast agent gadoxetate: a systematic comparison to multipurpose agents in rats. Invest Radiol. 2019;54:468–474.
Frenzel T, Apte C, Jost G, et al. Quantification and assessment of the chemical form of residual gadolinium in the brain after repeated administration of gadolinium-based contrast agents comparative study in rats. Invest Radiol. 2017;52:396–404.
Radbruch A, Richter H, Fingerhut S, et al. Gadolinium deposition in the brain in a large animal model. Invest Radiol. 2019;54:531–536.
Deike-Hofmann K, Reuter J, Haase R, et al. Glymphatic pathway of gadolinium-based contrast agents through the brain: overlooked and misinterpreted. Invest Radiol. 2019;54:229–237.
Jost G, Frenzel T, Lohrke J, et al. Penetration and distribution of gadolinium-based contrast agents into the cerebrospinal fluid in healthy rats: a potential pathway of entry into the brain tissue. Eur Radiol. 2017;27:2877–2885.
Radbruch A, Roberts DR, Clement O, et al. Chelated or dechelated gadolinium deposition. Lancet Neurol. 2017;16:955.
Quattrocchi CC, Errante Y, Mallio CA, et al. Effect of age on high T1 signal intensity of the dentate nucleus and globus pallidus in a large population exposed to gadodiamide. Invest Radiol. 2018;53:214–222.
McDonald RJ, McDonald JS, Kallmes DF, et al. Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology. 2015;275:772–782.
Kanda T, Nakai Y, Oba H, et al. Gadolinium deposition in the brain. Magn Reson Imaging. 2016;34:1346–1350.